BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy

Article English OPEN
Jan Dörrie ; Lek Babalija ; Stefanie Hoyer ; Kerstin F. Gerer ; Gerold Schuler ; Lucie Heinzerling ; Niels Schaft (2018)
  • Publisher: MDPI AG
  • Journal: International Journal of Molecular Sciences, volume 19, issue 1 (issn: 1422-0067, eissn: 1422-0067)
  • Related identifiers: pmc: PMC5796234, doi: 10.3390/ijms19010289
  • Subject: Chemistry | BRAF inhibitor | QD1-999 | vemurafenib | melanoma | cobimetinib | Article | QH301-705.5 | trametinib | kinase inhibitor | CAR-T cell | immunotherapy | MEK inhibitor | dabrafenib | Biology (General)

BRAF and MEK inhibitors (BRAFi/MEKi), the standard treatment for patients with BRAFV600 mutated melanoma, are currently explored in combination with various immunotherapies, notably checkpoint inhibitors and adoptive transfer of receptor-transfected T cells. Since two B... View more
Share - Bookmark